HEPATAMINE 8% Drug Patent Profile
✉ Email this page to a colleague
When do Hepatamine 8% patents expire, and when can generic versions of Hepatamine 8% launch?
Hepatamine 8% is a drug marketed by B Braun and is included in one NDA.
The generic ingredient in HEPATAMINE 8% is amino acids. There are three hundred and fifty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amino acids profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hepatamine 8%
A generic version of HEPATAMINE 8% was approved as amino acids by B BRAUN on April 13th, 2012.
Summary for HEPATAMINE 8%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HEPATAMINE 8% at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HEPATAMINE 8%
US Patents and Regulatory Information for HEPATAMINE 8%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
B Braun | HEPATAMINE 8% | amino acids | INJECTABLE;INJECTION | 018676-001 | Aug 3, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HEPATAMINE 8%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
B Braun | HEPATAMINE 8% | amino acids | INJECTABLE;INJECTION | 018676-001 | Aug 3, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HEPATAMINE 8%
See the table below for patents covering HEPATAMINE 8% around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
India | 143663 | A PROCESS FOR THE OBTENTION OF AMINO ACID FORMULATIONS FORPATIENTS WITH LIVER DISEASE | ⤷ Try a Trial |
Sweden | 7514589 | ⤷ Try a Trial | |
France | 2299023 | ⤷ Try a Trial | |
New Zealand | 179655 | A MIXTURE OF ESSENTIAL AND NON-ESSENTIAL AMINO ACIDS FOR HUMANS | ⤷ Try a Trial |
United Kingdom | 1507951 | ⤷ Try a Trial | |
Israel | 48621 | ⤷ Try a Trial | |
Japan | S51118839 | AMINO ACID PHARMACY FOR LIVERISH PATIENT DOSAGE | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for HEPATAMINE 8%
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0658161 | SPC/GB01/003 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: N-(4-(2(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MALEIC ACID, "ROSIGLITAZONE MALEATE", ITS TAUTOMERS AND PHARMACEUTICALLY ACCEPTABLE SOLVATES; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711 |
0306228 | SPC/GB01/002 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711 |
2404919 | 93073 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ACIDE BENZOIQUE 3-{6-{-1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBONYL AMINO}-3-METHYLPYRIDIN-2-YL}, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, OU UN PRO-MEDICAMENT DE TYPE ESTER DE CELUI-CI; FIRST REGISTRATION DATE: 20151124 |
1412357 | C 2007 091 | Romania | ⤷ Try a Trial | PRODUCT NAME: (3R)-3-AMINO-1-[9-(TRIFLUOROMETIL)-1,4,7,8-TETRAZABICICLO[4.3.0]NONA-6,8-DIEN-4-IL]-4-(2,4,5-TRIFLUOROFENIL)BUTAN-1-ONA - SITAGLIPTIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/383/001 - RO EU/1/07/383/018; DATE OF NATIONAL AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001 - EU/1/07/383/018; DATE OF FIRST AUTHORISATION IN EEA: 20070321 |
1870100 | 2012/024 | Ireland | ⤷ Try a Trial | PRODUCT NAME: ETHYL 3-((2-(4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)- PHENYLAMINO)-METHY)-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)- PYRIDIN-2-YL-AMINO)-PROPIONATE METHANESULPHONATE |
0933372 | SPC/GB08/018 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712 |
0147850 | SPC/GB98/042 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-ETHOXY-4-(1-(2-PIPERIDINO-PHENYL)-3-METHYL-1-BUTYL)-AMINOCARBONYLMETHYL)-BENZOIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT AND/OR OPTIONALLY IN THE FORM OF AN ENANTIOMER, IN PARTICULAR (S)(+)-2-ETHOXY-4-(1-(2-PIPERIDINO-PHENYL)-3; REGISTERED: UK EU/1/98/076/001 19980817; UK EU/1/98/076/002 19980817; UK EU/1/98/076/003 19980817; UK EU/1/98/076/004 19980817; UK EU/1/98/076/005 19980817; UK EU/1/98/076/006 19980817; UK EU/1/98/076/019 19980817; UK EU/1/98/076/020 19980817; UK EU/1/98/076/021 19980817; UK EU/1/98/076/013 19980817; UK EU/1/98/076/014 19980817; UK EU/1/98/076/015 19980817; UK EU/1/98/076/016 19980817; UK EU/1/98/076/017 19980817; UK EU/1/98/ |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |